This research program combines biomedical engineering efforts at Riverside Research Institute (RRI) and biological and medical investigations at Cornell University Medical College (CUMC). The ultimate objectives of the research are: 1) to develop reliable ultrasonic techniques for treating ocular tumors that threaten life and sight; and 2) to assure the safe use of promising new diagnostic ultrasound techniques that promise perhaps revolutionary advances for combatting ocular diseases. Both objectives involve comprehensive, scientific investigations of how ultrasonic energy modifies tissue. Therapy investigations involve the development of intense, short-term ultrasound exposures to treat tumors before blood-flow cooling and attendant uncertainties become significant. Special ultrasound transducers will be developed to reliably induce asymmetric lesions for producing efficient lesion matrices that cover extensive tumor volumes. A comprehensive computer simulation provides a model of relevant beam propagation and tissue heating. In-vivo ultrasonic spectrum analysis techniques and 3-D scanning are used together with histopathology and biologic assays to characterize induced in-vivo changes in human tumor explants. Remote temperature estimations are also being investigated. Safety studies involve ultrasonic pulsed Doppler exposures of the eye, with particular attention to the potential for thermal damage in the absorptive, avascular ocular lens. Very-high-frequency ultrasound systems, which can resolve fine-scale microstructures (e.g., 30-microM dimensions), are also under study; these systems apply frequencies (e.g., 50 MHz and above) that are much higher than those previously used in biological-effects experiments. The combined use of these systems with contrast agents will also be investigated from a safety perspective. Safety will be experimentally investigated by employing these techniques in animal eyes with comprehensive follow-up examinations. A theoretical model for safety will be established. These studies are intended to identify procedures and design criteria needed to support the continued development and safe use of modern ultrasonic capabilities. This program will result in a comprehensive data base and a validated model of ultrasonic effects for extrapolating results to humans. The model will also provide fundamental information regarding non-invasive tumor therapy and diagnostic safety for a broad spectrum of medical applications.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY010369-05
Application #
2684559
Study Section
Special Emphasis Panel (ZRG7-DMG (01))
Project Start
1994-04-01
Project End
2001-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Riverside Research Institute
Department
Type
DUNS #
046822615
City
New York
State
NY
Country
United States
Zip Code
10038
Lizzi, Frederic L; Muratore, Robert; Deng, Cheri X et al. (2003) Radiation-force technique to monitor lesions during ultrasonic therapy. Ultrasound Med Biol 29:1593-605
Deng, Cheri X; Lizzi, Frederic L (2002) A review of physical phenomena associated with ultrasonic contrast agents and illustrative clinical applications. Ultrasound Med Biol 28:277-86
Silverman, R H; Lizzi, F L; Ursea, B G et al. (2001) Safety levels for exposure of cornea and lens to very high-frequency ultrasound. J Ultrasound Med 20:979-86
Deng, C X; Lizzi, F L; Kalisz, A et al. (2000) Study of ultrasonic contrast agents using a dual-frequency band technique. Ultrasound Med Biol 26:819-31
Lizzi, F L; Deng, C X; Lee, P et al. (1999) A comparison of ultrasonic beams for thermal treatment of ocular tumors. Eur J Ultrasound 9:71-8
Deng, C X; Lizzi, F L; Silverman, R H et al. (1998) Imaging and spectrum analysis of contrast agents in the in vivo rabbit eye using very-high-frequency ultrasound. Ultrasound Med Biol 24:383-94
Coleman, D J; Silverman, R H; Ursea, R et al. (1997) Ultrasonically induced hyperthermia for adjunctive treatment of intraocular malignant melanoma. Retina 17:109-17